Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer

Nearly all cases of cervical cancer are initiated by persistent infection with high-risk strains of human papillomavirus (hr-HPV). When hr-HPV integrates into the host genome, the constitutive expression of oncogenic HPV proteins E6 and E7 function to disrupt p53 and retinoblastoma regulation of cel...

Full description

Bibliographic Details
Main Authors: Zewei Jiang, Joseph Albanese, Joshua Kesterson, Joshua Warrick, Rouzan Karabakhtsian, Ekaterina Dadachova, Rébécca Phaëton
Format: Article
Language:English
Published: Elsevier 2019-10-01
Series:Translational Oncology
Online Access:http://www.sciencedirect.com/science/article/pii/S193652331930018X
id doaj-7a79adf7076c4f8caf013fd250ed9164
record_format Article
spelling doaj-7a79adf7076c4f8caf013fd250ed91642020-11-25T01:16:24ZengElsevierTranslational Oncology1936-52332019-10-01121012891295Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical CancerZewei Jiang0Joseph Albanese1Joshua Kesterson2Joshua Warrick3Rouzan Karabakhtsian4Ekaterina Dadachova5Rébécca Phaëton6Albert Einstein College of Medicine, Montefiore Medical Center, Department of Radiology, 1300 Morris Park Avenue, Bronx, NY 10461, United StatesAlbert Einstein College of Medicine, Montefiore Medical Center, 111 East 210th Street Avenue, Bronx, NY 10467, United StatesPenn State College of Medicine, Milton S. Hershey Medical Center, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, 500 University Avenue, Mail Code H103, Hershey, PA 17033Penn State College of Medicine, Milton S. Hershey Medical Center, Department of Pathology, 500 University Avenue, Hershey, PA 17033, United StatesAlbert Einstein College of Medicine, Montefiore Medical Center, 1300 Morris Park Avenue, Bronx, NY 10461, United StatesUniversity of Saskatchewan, College of Pharmacy and Nutrition, 107 Wiggins Rd, Health Sciences Blvd, Box 3D01-11, Saskatoon, Saskatchewan, S7N 5E5, CanadaPenn State College of Medicine, Departments of Obstetrics and Gynecology and Microbiology and Immunology, Division of Gynecologic Oncology, 500 University Drive, Mail Code H103, Hershey, PA 17033; Corresponding author at: Department of Obstetrics and Gynecology and Microbiology and Immunology, Division of Gynecologic Oncology 500 University Drive, Hershey, PA 17033, United States.Nearly all cases of cervical cancer are initiated by persistent infection with high-risk strains of human papillomavirus (hr-HPV). When hr-HPV integrates into the host genome, the constitutive expression of oncogenic HPV proteins E6 and E7 function to disrupt p53 and retinoblastoma regulation of cell cycle, respectively, to favor malignant transformation. HPV E6 and E7 are oncogenes found in over 99% of cervical cancer, they are also expressed in pre-neoplastic stages making these viral oncoproteins attractive therapeutic targets. Monoclonal antibodies (mAbs) represent a novel potential approach against the actions of hr-HPV E6 and E7 oncoproteins.In this report, we describe the utilization of anti-HPV E6 and HPV E7 mAbs in an experimental murine model of human cervical cancer tumors. We used differential dosing strategies of mAbs C1P5 (anti-HPV 16 E6) and TVG701Y (anti-HPV E7) administered via intraperitoneal or intratumoral injections. We compared mAbs to the action of chemotherapeutic agent Cisplatin and demonstrated the capacity of mAbs to significantly inhibit tumor growth. Furthermore, we investigated the contribution of the immune system and found increased complement deposition in both C1P5 and TVG701Y treated tumors compared to irrelevant mAb therapy. Taken together, the results suggest that anti-HPV E6 and E7 mAbs exert inhibition of tumor growth in a viral-specific manner and stimulate an immune response that could be exploited for an additional treatment options for patients. Keywords: cervical cancer, monoclonal antibodies, HPV E6 and E7, immunotherapy, nude micehttp://www.sciencedirect.com/science/article/pii/S193652331930018X
collection DOAJ
language English
format Article
sources DOAJ
author Zewei Jiang
Joseph Albanese
Joshua Kesterson
Joshua Warrick
Rouzan Karabakhtsian
Ekaterina Dadachova
Rébécca Phaëton
spellingShingle Zewei Jiang
Joseph Albanese
Joshua Kesterson
Joshua Warrick
Rouzan Karabakhtsian
Ekaterina Dadachova
Rébécca Phaëton
Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer
Translational Oncology
author_facet Zewei Jiang
Joseph Albanese
Joshua Kesterson
Joshua Warrick
Rouzan Karabakhtsian
Ekaterina Dadachova
Rébécca Phaëton
author_sort Zewei Jiang
title Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer
title_short Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer
title_full Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer
title_fullStr Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer
title_full_unstemmed Monoclonal Antibodies Against Human Papillomavirus E6 and E7 Oncoproteins Inhibit Tumor Growth in Experimental Cervical Cancer
title_sort monoclonal antibodies against human papillomavirus e6 and e7 oncoproteins inhibit tumor growth in experimental cervical cancer
publisher Elsevier
series Translational Oncology
issn 1936-5233
publishDate 2019-10-01
description Nearly all cases of cervical cancer are initiated by persistent infection with high-risk strains of human papillomavirus (hr-HPV). When hr-HPV integrates into the host genome, the constitutive expression of oncogenic HPV proteins E6 and E7 function to disrupt p53 and retinoblastoma regulation of cell cycle, respectively, to favor malignant transformation. HPV E6 and E7 are oncogenes found in over 99% of cervical cancer, they are also expressed in pre-neoplastic stages making these viral oncoproteins attractive therapeutic targets. Monoclonal antibodies (mAbs) represent a novel potential approach against the actions of hr-HPV E6 and E7 oncoproteins.In this report, we describe the utilization of anti-HPV E6 and HPV E7 mAbs in an experimental murine model of human cervical cancer tumors. We used differential dosing strategies of mAbs C1P5 (anti-HPV 16 E6) and TVG701Y (anti-HPV E7) administered via intraperitoneal or intratumoral injections. We compared mAbs to the action of chemotherapeutic agent Cisplatin and demonstrated the capacity of mAbs to significantly inhibit tumor growth. Furthermore, we investigated the contribution of the immune system and found increased complement deposition in both C1P5 and TVG701Y treated tumors compared to irrelevant mAb therapy. Taken together, the results suggest that anti-HPV E6 and E7 mAbs exert inhibition of tumor growth in a viral-specific manner and stimulate an immune response that could be exploited for an additional treatment options for patients. Keywords: cervical cancer, monoclonal antibodies, HPV E6 and E7, immunotherapy, nude mice
url http://www.sciencedirect.com/science/article/pii/S193652331930018X
work_keys_str_mv AT zeweijiang monoclonalantibodiesagainsthumanpapillomaviruse6ande7oncoproteinsinhibittumorgrowthinexperimentalcervicalcancer
AT josephalbanese monoclonalantibodiesagainsthumanpapillomaviruse6ande7oncoproteinsinhibittumorgrowthinexperimentalcervicalcancer
AT joshuakesterson monoclonalantibodiesagainsthumanpapillomaviruse6ande7oncoproteinsinhibittumorgrowthinexperimentalcervicalcancer
AT joshuawarrick monoclonalantibodiesagainsthumanpapillomaviruse6ande7oncoproteinsinhibittumorgrowthinexperimentalcervicalcancer
AT rouzankarabakhtsian monoclonalantibodiesagainsthumanpapillomaviruse6ande7oncoproteinsinhibittumorgrowthinexperimentalcervicalcancer
AT ekaterinadadachova monoclonalantibodiesagainsthumanpapillomaviruse6ande7oncoproteinsinhibittumorgrowthinexperimentalcervicalcancer
AT rebeccaphaeton monoclonalantibodiesagainsthumanpapillomaviruse6ande7oncoproteinsinhibittumorgrowthinexperimentalcervicalcancer
_version_ 1725149892385439744